Literature DB >> 10198537

Comparative mitogenic potencies of EGF and TGF alpha and their dependence on receptor-limitation versus ligand-limitation.

C C Reddy1, A Wells, D A Lauffenburger.   

Abstract

Transforming growth factor alpha (TGF alpha) has been reported to be a more potent agonist when compared to epidermal growth factor (EGF) in several systems while acting via their common receptor, the epidermal growth factor receptor (EGFR). It has been postulated that this increased potency is mediated by the increased recycling of EGFR upon activation by TGF alpha as against receptor activation by EGF. The authors test this hypothesis by simultaneously measuring mitogenesis and the dynamics of surface receptor number in response to these ligands in NR6 mouse fibroblasts expressing the EGFR. The data demonstrates that increased receptor recycling due to endosomal dissociation of TGF alpha can indeed realise an increased mitogenic potency relative to EGF under appropriate cellular and experimental conditions (i.e. situations in which the increase in the number of occupied receptors due to receptor sparing by TGF alpha represents additional mitogenic signalling capacity). However, this difference in receptor trafficking does not uniquely determine the relative potencies of these ligands since TGF alpha is a less potent mitogen compared to EGF when experimental conditions are dominated by the effects of ligand trafficking on growth factor availability. Thus, the relative potencies of these growth factors are determined in a given context by the relative importance of ligand and receptor trafficking effects which determine the availability of these signalling components. These results are consistent with a suggested model of hormone responsiveness which favours dissociative ligands (such as TGF alpha) in receptor-limited situations and non-dissociative ligands (such as EGF) in the case of ligand limitation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10198537     DOI: 10.1007/bf02523222

Source DB:  PubMed          Journal:  Med Biol Eng Comput        ISSN: 0140-0118            Impact factor:   2.602


  20 in total

1.  Engineering dynamics of growth factors and other therapeutic ligands.

Authors:  D A Lauffenburger; L Chu; A French; G Oehrtman; C Reddy; A Wells; S Niyogi; H S Wiley
Journal:  Biotechnol Bioeng       Date:  1996-10-05       Impact factor: 4.530

2.  Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes.

Authors:  R Ebner; R Derynck
Journal:  Cell Regul       Date:  1991-08

3.  Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha.

Authors:  M Korc; J E Finman
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

4.  Variants of 3T3 cells lacking mitogenic response to epidermal growth factor.

Authors:  R M Pruss; H R Herschman
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

5.  Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha.

Authors:  I Lax; A Johnson; R Howk; J Sap; F Bellot; M Winkler; A Ullrich; B Vennstrom; J Schlessinger; D Givol
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

6.  Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction.

Authors:  A R French; D K Tadaki; S K Niyogi; D A Lauffenburger
Journal:  J Biol Chem       Date:  1995-03-03       Impact factor: 5.157

7.  Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention.

Authors:  J J Herbst; L K Opresko; B J Walsh; D A Lauffenburger; H S Wiley
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

8.  Ligand-induced transformation by a noninternalizing epidermal growth factor receptor.

Authors:  A Wells; J B Welsh; C S Lazar; H S Wiley; G N Gill; M G Rosenfeld
Journal:  Science       Date:  1990-02-23       Impact factor: 47.728

9.  Sequence-specific 1H-NMR assignments and identification of two small antiparallel beta-sheets in the solution structure of recombinant human transforming growth factor alpha.

Authors:  G T Montelione; M E Winkler; L E Burton; E Rinderknecht; M B Sporn; G Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

10.  Engineering epidermal growth factor for enhanced mitogenic potency.

Authors:  C C Reddy; S K Niyogi; A Wells; H S Wiley; D A Lauffenburger
Journal:  Nat Biotechnol       Date:  1996-12       Impact factor: 54.908

View more
  9 in total

1.  Cellular level models as tools for cytokine design.

Authors:  Mala L Radhakrishnan; Bruce Tidor
Journal:  Biotechnol Prog       Date:  2010 Jul-Aug

2.  Where EGF receptors transmit their signals.

Authors:  Nancy L Lill; Nurettin Ilter Sever
Journal:  Sci Signal       Date:  2012-09-25       Impact factor: 8.192

3.  Growth Factor Identity Is Encoded by Discrete Coiled-Coil Rotamers in the EGFR Juxtamembrane Region.

Authors:  Amy Doerner; Rebecca Scheck; Alanna Schepartz
Journal:  Chem Biol       Date:  2015-06-18

Review 4.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

5.  An integrated model of epidermal growth factor receptor trafficking and signal transduction.

Authors:  Haluk Resat; Jonathan A Ewald; David A Dixon; H Steven Wiley
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

6.  Cell surface restriction of EGFR by a tenascin cytotactin-encoded EGF-like repeat is preferential for motility-related signaling.

Authors:  Anand Krishnan V Iyer; Kien T Tran; Linda Griffith; Alan Wells
Journal:  J Cell Physiol       Date:  2008-02       Impact factor: 6.384

7.  Development of an epidermal growth factor derivative with EGFR blocking activity.

Authors:  Clara Panosa; Francesc Tebar; Montserrat Ferrer-Batallé; Humphrey Fonge; Masaharu Seno; Raymond M Reilly; Anna Massaguer; Rafael De Llorens
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

8.  HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Authors:  Laurence Booth; Jane L Roberts; Andrew Poklepovic; Francesca Avogadri-Connors; Richard E Cutler; Alshad S Lalani; Paul Dent
Journal:  Oncotarget       Date:  2017-10-09

9.  Receptor-based mechanism of relative sensing and cell memory in mammalian signaling networks.

Authors:  Eugenia Lyashenko; Mario Niepel; Purushottam D Dixit; Sang Kyun Lim; Peter K Sorger; Dennis Vitkup
Journal:  Elife       Date:  2020-01-21       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.